Zebra Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Zebra Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,123	Closed	-$103K	–	466
2019 Q2	$103K	Sell	11,123 -1,730	-13%	-$20K	0.05%	439
2019 Q1	$179K	Sell	12,853 -1,543	-11%	-$17.6K	0.1%	391
2018 Q4	$157K	Buy	+14,396	New	+$152K	0.1%	342

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zebra Capital Management's CCXI Position: Q3 2019 in Review

Zebra Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2019, closing a stake of 11,123 shares — an estimated $103K sold.

Zebra Capital Management first reported a position in CCXI in Q4 2018 and held it in 3 quarters. The position peaked at $179K in Q1 2019. 100 funds tracked by Wall St. Rank hold CCXI as of Q3 2019.

Zebra Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2019 after selling out during the quarter.
Zebra Capital Management sold 11,123 ChemoCentryx, Inc. shares in Q3 2019, an estimated $103K.
Zebra Capital Management first reported a position in ChemoCentryx, Inc. in Q4 2018 and held it in 3 quarters.
Zebra Capital Management's ChemoCentryx, Inc. position peaked at $179K in Q1 2019.
100 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2019.

Based on Zebra Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.